GENENTECH NUTROPIN CLEARED BY FDA FOR hGH DEFICIENCY MARCH 8 AS LILLY'S HUMATROPE LOSES ORPHAN EXCLUSIVITY; FOUR OTHER GROWTH HORMONE PRODUCTS PENDING
Executive Summary
Genentech's Nutropin (somatropin) received IDA approval for treatment of short stature caused by human growth hormone deficiency on March 8, the day Lilly's Humatrope (somatropin) lost orphan drug exclusivity for that indication.